| STUB1 mutations in autosomal recessive ataxias – evidence for mutation-specific clinical heterogeneity K Heimdal, M Sanchez-Guixé, I Aukrust, J Bollerslev, O Bruland, ... Orphanet journal of rare diseases 9, 1-12, 2014 | 81 | 2014 |
| Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? C Hierro, M Alsina, M Sánchez, V Serra, J Rodon, J Tabernero Annals of Oncology 28 (6), 1207-1216, 2017 | 42 | 2017 |
| High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer M Palafox, L Monserrat, M Bellet, G Villacampa, A Gonzalez-Perez, ... Nature communications 13 (1), 5258, 2022 | 41 | 2022 |
| In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins Y Pakdaman, M Sanchez-Guixe, R Kleppe, S Erdal, HJ Bustad, ... Bioscience reports 37 (2), BSR20170251, 2017 | 31 | 2017 |
| Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts A Gris-Oliver, M Palafox, L Monserrat, F Brasó-Maristany, A Òdena, ... Clinical Cancer Research 26 (14), 3720-3731, 2020 | 29 | 2020 |
| High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer M Sánchez-Guixé, C Hierro, J Jiménez, C Viaplana, G Villacampa, ... Clinical Cancer Research 28 (1), 137-149, 2022 | 14 | 2022 |
| PI3K activation promotes resistance to eribulin in HER2-negative breast cancer A Gris-Oliver, YH Ibrahim, MA Rivas, C García-García, M Sánchez-Guixé, ... British Journal of Cancer 124 (9), 1581-1591, 2021 | 14 | 2021 |
| The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and … M Lawson, N Cureton, S Ros, A Cheraghchi-Bashi, J Urosevic, S D'Arcy, ... Cancer Research 83 (23), 3989-4004, 2023 | 5 | 2023 |
| Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues M Sánchez-Guixé, F Muiños, M Pinheiro-Santin, V González-Huici, ... Cancer Discovery, OF1-OF12, 2024 | 2 | 2024 |
| FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh) C Hierro, M Sánchez-Guixé, F Ruiz-Pace, J Jimenez, L Maynes, A Azaro, ... Annals of Oncology 28, v575, 2017 | 2 | 2017 |
| 29P FGFR1-4 high mRNA expression (mRNAh) as predictive biomarker for FGFR inhibitors in breast cancer (BC) C Hierro, M Sánchez-Guixé, J Jiménez, E Garralda, C Saura, P Nuciforo, ... Annals of Oncology 31, S9-S10, 2020 | 1 | 2020 |
| In-vitro characterization of STUB1 mutations in recessively inherited spinocerebellar ataxia-16 Y Pakdaman The University of Bergen, 2016 | 1 | 2016 |
| THE ORIGIN AND EVOLUTION OF PEDIATRIC SECONDARY NEOPLASMS M Sanchez-Guixe, F Muinos, C Lavarino, J Mora, A Gonzalez Perez, ... PEDIATRIC BLOOD & CANCER 70, S123-S123, 2023 | | 2023 |
| High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer M Palafox Sánchez, L Monserrat Vicente, A Gonzalez-Perez, ... Nature Portfolio, 2022 | | 2022 |
| The impact and function of C-terminal degrons and protein misfolding in the degradation of truncated proteins M Sánchez Guixé | | 2020 |
| ER+ metastatic breast cancer targeted therapy: biomarkers of response and mechanisms of resistance to PI3K and FGFR inhibitors M Sánchez Guixé | | 2020 |
| Functional Characterization of Mutations in STUB1, a Protein Involved in the Protein Turnover System, in Patients with Autosomal Recessive Cerebellar Ataxia M Sánchez Guixé | | 2014 |
